Last reviewed · How we verify
Trospium Cl
Trospium chloride is an anticholinergic agent that blocks muscarinic receptors in the bladder smooth muscle, reducing involuntary contractions and urinary urgency.
Trospium chloride is an anticholinergic agent that blocks muscarinic receptors in the bladder smooth muscle, reducing involuntary contractions and urinary urgency. Used for Overactive bladder with symptoms of urge incontinence, urgency, and frequency.
At a glance
| Generic name | Trospium Cl |
|---|---|
| Also known as | Trosec |
| Sponsor | Toronto Rehabilitation Institute |
| Drug class | Anticholinergic agent |
| Target | Muscarinic acetylcholine receptors (M3 subtype) |
| Modality | Small molecule |
| Therapeutic area | Urology |
| Phase | FDA-approved |
Mechanism of action
Trospium chloride competitively antagonizes muscarinic acetylcholine receptors on detrusor smooth muscle in the bladder. By blocking these receptors, it decreases the frequency and amplitude of bladder contractions, thereby reducing symptoms of overactive bladder such as urgency, frequency, and urge incontinence. As a quaternary ammonium compound, it has limited blood-brain barrier penetration, which may reduce central nervous system side effects compared to tertiary amine anticholinergics.
Approved indications
- Overactive bladder with symptoms of urge incontinence, urgency, and frequency
Common side effects
- Dry mouth
- Constipation
- Headache
- Dizziness
- Blurred vision
Key clinical trials
- A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2) (PHASE3)
- A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1) (PHASE3)
- Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3) (PHASE3)
- A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1) (PHASE3)
- A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2) (PHASE3)
- A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3) (PHASE3)
- A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (PHASE3)
- A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Trospium Cl CI brief — competitive landscape report
- Trospium Cl updates RSS · CI watch RSS
- Toronto Rehabilitation Institute portfolio CI